CELLeBRAIN Raises $1M Seed for Stem Cell Therapies Targeting Glioblastoma

CELLeBRAIN (셀레브레인), a South Korean clinical-stage biotechnology company, has raised $1 million in Seed funding. The round was led by Lutz Birnbaumer, with participation from Mariel Birnbaumer.

What CELLeBRAIN Does

CELLeBRAIN develops stem cell-based gene and cell therapies for cancers and chronic degenerative diseases with limited treatment options. The company also develops regenerative therapies and genome-analysis technology.

Its work sits at the clinical stage, meaning its programs have moved beyond preclinical research into human trials.

Lead Candidate: CB-11 for Glioblastoma

The company's lead candidate, CB-11, targets glioblastoma (GBM). In February 2026, CB-11 received US FDA orphan drug designation.

The program has completed a Phase 1 trial in recurrent GBM patients in Korea. A Phase 1 trial in newly diagnosed patients is currently underway.

Regulatory Path in the United States

CELLeBRAIN is preparing a US investigational new drug application targeted for 2027. That filing would be a key step toward running clinical trials in the United States and expanding the CB-11 program beyond its Korean trial sites.

The Round at a Glance

Company: CELLeBRAIN (셀레브레인)
Round type: Seed
Amount raised: $1,000,000 USD
Announced: September 8, 2026
Lead investor: Lutz Birnbaumer
Additional investors: Mariel Birnbaumer
Stage: Seed

Why Glioblastoma Is a Difficult Target

Glioblastoma is an aggressive brain cancer with limited treatment options, which is the therapeutic gap CELLeBRAIN's CB-11 program is designed to address. The FDA orphan drug designation granted in February 2026 reflects the program's focus on a serious condition with unmet medical need.

CELLeBRAIN's broader pipeline extends beyond oncology. The company is also developing therapies for chronic degenerative diseases and regenerative medicine applications, alongside genome-analysis technology.

What Comes Next

With $1 million in Seed funding led by Lutz Birnbaumer and backed by Mariel Birnbaumer, CELLeBRAIN continues to advance its clinical-stage programs. The near-term milestones are clear from the company's disclosed plans: an ongoing Phase 1 trial in newly diagnosed GBM patients, following the completed Phase 1 in recurrent GBM patients in Korea, and preparation of a US investigational new drug application targeted for 2027.

For observers of cell and gene therapy in oncology, CELLeBRAIN represents a Korean clinical-stage developer pursuing a stem cell-based approach to one of the hardest-to-treat cancers, with a US regulatory pathway now in preparation.